An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Sponsor:

Zai Biopharmaceutical

Sponsor Study ID:

ZL-1310-001

CTO #:

103950

NCT Number:

NCT06179069

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

To characterize the safety and tolerability of different dose levels of ZL-1310, including dose limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose (RD).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)